<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614818</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-289-01</org_study_id>
    <nct_id>NCT04614818</nct_id>
  </id_info>
  <brief_title>A Multi-center, Retrospective Analysis of Clinical Character, Outcome and Prognosis of Lymphoepithelioma-like Carcinoma</brief_title>
  <official_title>A Multi-center, Retrospective Analysis of Clinical Character, Outcome and Prognosis of Lymphoepithelioma-like Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators retrospective collect the clinical data of patients diagnosed with&#xD;
      lymphoepithelioma-like carcinoma, including primary site, gender, age, smoking history, tumor&#xD;
      stage, time of initial treatment, EBV-DNA copy number, first-line treatment and survival&#xD;
      status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoepithelioma-like carcinoma (LELC) is a rare EBV-related tumor. Its histology is similar&#xD;
      to that of nasopharyngeal carcinoma. In 2004, the WHO classified LELC into one subtype of&#xD;
      large cell carcinoma, and the 2015 WHO classified it as other and unclassified cancers. LELC&#xD;
      can originate in many organs, including parotid glands, throat, lungs, digestive tract,&#xD;
      genitourinary system, etc. Driver gene mutations are rarely seen, and most of them are PD-L1&#xD;
      positive. In terms of treatment, there is no standard first-line treatment for&#xD;
      lymphoepithelioma-like cancer. Patients with early-stage lymphoepithelioma-like cancer can&#xD;
      receive surgery or radiotherapy, while palliative radiotherapy or chemotherapy is the main&#xD;
      treatment for patients in advanced stage. The survival time is about 107 months, the 5-year&#xD;
      OS is 59.5%, which is better than the prognosis of lung squamous cell carcinoma in the same&#xD;
      period. A retrospective study of Sun yat-sen University Cancer Hospital included 127 patients&#xD;
      with advanced lung LELC who received first-line chemotherapy between 2007 and 2018.&#xD;
      Gemcitabine and platinum based chemotherapy and paclitaxel and platinum based regimens are&#xD;
      significantly better than pemetrexed and platinum, but most of the current studies on&#xD;
      lymphoepithelioma-like cancer focus on LELC that originates in the lung. But for other sites,&#xD;
      such as parotid glands, liver, digestive tract, are mostly based on case reports, and there&#xD;
      are few retrospective studies with large samples to explore their clinical features and&#xD;
      treatment outcome. Therefore, investigators designed this retrospective clinical study to&#xD;
      analyze the clinical characteristics, treatment, survival, and prognostic risk factors of&#xD;
      patients with lymphoepithelioma-like carcinoma in order to summary the clinical character and&#xD;
      guide treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.</time_frame>
    <description>The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 24 months.</time_frame>
    <description>The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.</description>
  </secondary_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Lymphoepithelioma-Like Carcinoma</condition>
  <condition>Lymphoepithelioma-Like Carcinoma of Thymus</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>pulmonary lymphoepithelioma-like carcinoma</arm_group_label>
    <description>The primary site of lymphoepithelioma-like carcinoma locates in the lungs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lymphoepithelioma-like carcinoma of thymus</arm_group_label>
    <description>The primary site of lymphoepithelioma-like carcinoma locates in the thymus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lymphoepithelioma-like carcinoma of salivary glands</arm_group_label>
    <description>The primary site of lymphoepithelioma-like carcinoma locates in the parotid gland or submandibular gland.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lymphoepithelioma-like carcinoma of stomach</arm_group_label>
    <description>The primary site of lymphoepithelioma-like carcinoma locates in the stomach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lymphoepithelioma-like carcinoma of esophagus</arm_group_label>
    <description>The primary site of lymphoepithelioma-like carcinoma locates in the esophagus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lymphoepithelioma-like carcinoma of liver</arm_group_label>
    <description>The primary site of lymphoepithelioma-like carcinoma locates in the liver.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lymphoepithelioma-like carcinoma of ovaries</arm_group_label>
    <description>The primary site of lymphoepithelioma-like carcinoma locates in the ovaries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lymphoepithelioma-like carcinoma of cervix</arm_group_label>
    <description>The primary site of lymphoepithelioma-like carcinoma locates in the cervix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lymphoepithelioma-like carcinoma of tonsil</arm_group_label>
    <description>The primary site of lymphoepithelioma-like carcinoma locates in the tonsil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-intervention research</intervention_name>
    <description>Non-intervention research</description>
    <arm_group_label>lymphoepithelioma-like carcinoma of cervix</arm_group_label>
    <arm_group_label>lymphoepithelioma-like carcinoma of esophagus</arm_group_label>
    <arm_group_label>lymphoepithelioma-like carcinoma of liver</arm_group_label>
    <arm_group_label>lymphoepithelioma-like carcinoma of ovaries</arm_group_label>
    <arm_group_label>lymphoepithelioma-like carcinoma of salivary glands</arm_group_label>
    <arm_group_label>lymphoepithelioma-like carcinoma of stomach</arm_group_label>
    <arm_group_label>lymphoepithelioma-like carcinoma of thymus</arm_group_label>
    <arm_group_label>lymphoepithelioma-like carcinoma of tonsil</arm_group_label>
    <arm_group_label>pulmonary lymphoepithelioma-like carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed diagnosis of lymphoepithelioma-like carcinoma of any primary site,&#xD;
        including lung, salivary glands, thymus, tonsil, liver, stomach, esophagus, ovary, cervix&#xD;
        et al.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Lymphoepithelioma-like carcinoma confirmed by histopathology;&#xD;
&#xD;
          -  2. The primary lesion does not involve the nasopharynx;&#xD;
&#xD;
          -  3. Complete data for patient's character, laboratory and imaging test, treatment and&#xD;
             follow-up are available.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Concomitant with other tumor components at the time of diagnosis;&#xD;
&#xD;
          -  2. Have a history of any other malignant tumors;&#xD;
&#xD;
          -  3. Lack of complete data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Sun yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei-ting Chen, Doctor</last_name>
      <email>chenmt@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wu Q, Wang W, Zhou P, Fu Y, Zhang Y, Shao YW, Jiang L. Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden. Pathol Res Pract. 2020 Aug;216(8):153043. doi: 10.1016/j.prp.2020.153043. Epub 2020 Jun 2.</citation>
    <PMID>32703503</PMID>
  </reference>
  <reference>
    <citation>Fang W, Hong S, Chen N, He X, Zhan J, Qin T, Zhou T, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Tang Y, Huang Y, Zhao H, Zhang L. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget. 2015 Oct 20;6(32):33019-32. doi: 10.18632/oncotarget.5028.</citation>
    <PMID>26361045</PMID>
  </reference>
  <reference>
    <citation>He J, Shen J, Pan H, Huang J, Liang W, He J. Pulmonary lymphoepithelioma-like carcinoma: a Surveillance, Epidemiology, and End Results database analysis. J Thorac Dis. 2015 Dec;7(12):2330-8. doi: 10.3978/j.issn.2072-1439.2015.12.62.</citation>
    <PMID>26793355</PMID>
  </reference>
  <reference>
    <citation>Abouelfad DM, Yassen NN, Amin HAA, Shabana ME. Lymphoepithelioma-Like Carcinoma of the Breast Mimicking Granulomatous Mastitis- Case Report and Review of the Literature. Asian Pac J Cancer Prev. 2017 Jul 27;18(7):1737-1741.</citation>
    <PMID>28749097</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Tongyu Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

